Capital Fund Management (CFM)
CRSP icon

Capital Fund Management (CFM)’s CRISPR Therapeutics CRSP Stock Holding History

Capital Fund Management (CFM)’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-41,300
Closed -$2.17M – 2145
2025
Q4 		$2.17M Buy
41,300
+2,800
+7% +$168K 0.01% 1666
2025
Q3 		$2.5M Sell
38,500
-8,400
-18% -$482K 0.01% 1665
2025
Q2 		$2.28M Buy
46,900
+11,600
+33% +$449K 0.01% 1598
2025
Q1 		$1.2M Sell
35,300
-48,500
-58% -$2.06M ﹤0.01% 1602
2024
Q4 		$3.3M Buy
83,800
+19,500
+30% +$921K 0.01% 1282
2024
Q3 		$3.02M Sell
64,300
-21,100
-25% -$1.07M 0.01% 1252
2024
Q2 		$4.61M Sell
85,400
-103,100
-55% -$5.96M 0.01% 989
2024
Q1 		$12.8M Buy
188,500
+167,300
+789% +$12M 0.04% 623
2023
Q4 		$1.33M Buy
+21,200
New +$1.17M ﹤0.01% 1728
2023
Q3 		– Sell
-23,900
Closed -$1.34M – 1957
2023
Q2 		$1.34M Sell
23,900
-126,500
-84% -$7.18M 0.01% 1317
2023
Q1 		$6.8M Buy
150,400
+72,600
+93% +$3.53M 0.03% 619
2022
Q4 		$3.16M Buy
77,800
+30,500
+64% +$1.62M 0.02% 792
2022
Q3 		$3.09M Buy
47,300
+17,500
+59% +$1.27M 0.02% 709
2022
Q2 		$1.81M Sell
29,800
-26,800
-47% -$1.58M 0.02% 869
2022
Q1 		$3.55M Buy
56,600
+34,100
+152% +$2.14M 0.03% 705
2021
Q4 		$1.71M Buy
+22,500
New +$1.97M 0.01% 1095
2021
Q2 		– Sell
-85,800
Closed -$10.5M – 1464
2021
Q1 		$10.5M Buy
+85,800
New +$13M 0.12% 221
2020
Q3 		– Sell
-16,500
Closed -$1.21M – 1216
2020
Q2 		$1.21M Sell
16,500
-1,100
-6% -$64.3K 0.02% 641
2020
Q1 		$746K Buy
+17,600
New +$909K 0.01% 893
2019
Q1 		– Sell
-17,100
Closed -$489K – 1726
2018
Q4 		$489K Sell
17,100
-32,500
-66% -$1.13M ﹤0.01% 1382
2018
Q3 		$2.2M Buy
+49,600
New +$2.6M 0.01% 1068

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital Fund Management (CFM)'s CRSP Position: Q2 2026 in Review

Capital Fund Management (CFM) reduced its CRISPR Therapeutics (CRSP) stake by 6.8% in Q2 2026, selling an estimated $344K and leaving 89,242 shares worth $4.87M. The position accounts for 0.02% of the portfolio, ranked #927.

Capital Fund Management (CFM) first reported a position in CRSP in Q3 2018 and has held it in 19 quarters since. The position peaked at $14.1M in Q3 2021. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Capital Fund Management (CFM) held 89,242 shares of CRISPR Therapeutics worth $4.87M as of Q2 2026.
  • Capital Fund Management (CFM) sold 6,528 CRISPR Therapeutics shares in Q2 2026, an estimated $344K.
  • CRISPR Therapeutics made up 0.02% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #927 holding.
  • Capital Fund Management (CFM) first reported a position in CRISPR Therapeutics in Q3 2018 and has held it in 19 quarters since.
  • Capital Fund Management (CFM)'s CRISPR Therapeutics position peaked at $14.1M in Q3 2021.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.